The present disclosure relates generally to medical methods, systems, and devices for performing endovascular interventions. More particularly, the present disclosure relates to methods and systems for access directly into the carotid artery to perform interventional procedures in the treatment of vascular disease and other diseases associated with the vasculature.
Interventional procedures are performed to treat vascular disease, for example stenosis, occlusions, aneurysms, or fistulae. Interventional procedures are also used to perform procedures on organs or tissue targets that are accessible via blood vessels, for example denervation or ablation of tissue to intervene in nerve conduction, embolization of vessels to restrict blood flow to tumors or other tissue, and delivery of drugs, contrast, or other agents to intra or extravascular targets for therapeutic or diagnostic purposes. Interventional procedures are typically divided into coronary, neurovascular, and peripheral vascular categories. Most procedures are performed in the arterial system via an arterial access site.
Methods for gaining arterial access to perform these procedures are well-established, and fall into two broad categories: percutaneous access and surgical cut-down. The majority of interventional procedures utilize a percutaneous access. For this access method, a needle puncture is made from the skin, through the subcutaneous tissue and muscle layers to the vessel wall, and into the vessel itself. Vascular ultrasound is often used to image the vessel and surrounding structures, and facilitate accurate insertion of the needle into the vessel. Depending on the size of the artery and of the access device, the method will vary, for example a Seldinger technique or modified Seldinger technique consists of placing a sheath guide wire through the needle into the vessel. Typically the sheath guide wire is 0.035″ or 0.038″. In some instances, a micro-puncture or micro access technique is used whereby the vessel is initially accessed by a small gauge needle, and successively dilated up by a 4F micropuncture cannula through which the sheath guidewire is placed. Once the guidewire is placed, an access sheath and sheath dilator are inserted over the guide wire into the artery. In other instances, for example if a radial artery is being used as an access site, a smaller sheath guidewire is used through the initial needle puncture, for example an 0.018″ guidewire. The dilator of a radial access sheath is designed to accommodate this smaller size guidewire, so that the access sheath and dilator can be inserted over the 0.018″ wire into the artery.
In a surgical cut-down, a skin incision is made and tissue is dissected away to the level of the target artery. This method is often used if the procedure requires a large access device, if there is risk to the vessel with a percutaneous access, and/or if there is possibility of unreliable closure at the access site at the conclusion of the procedure. Depending on the size of the artery and of the access device, an incision is made into the wall of the vessel with a blade, or the vessel wall is punctured directly by an access needle, through which a sheath guide wire is placed. The micropuncture technique may also be used to place a sheath guide wire. As above, the access sheath and sheath dilator are inserted into the artery over the sheath guide wire. Once the access sheath is placed, the dilator and sheath guide wire are removed. Devices can now be introduced via the access sheath into the artery and advanced using standard interventional techniques and fluoroscopy to the target site to perform the procedure.
Access to the target site is accomplished from an arterial access site that is easily entered from the skin. Usually this is the femoral artery which is both relatively large and relatively superficial, and easy to close on completion of the procedure using either direct compression or one of a variety of vessel closure devices. For this reason, endovascular devices are specifically designed for this femoral access site. However, the femoral artery and its vicinity are sometimes diseased, making it difficult or impossible to safely access or introduce a device into the vasculature from this site. In addition, the treatment target site may be quite some distance from the femoral access point requiring devices to be quite lengthy and cumbersome. Further, reaching the target site form the femoral access point may involve traversing tortuous and/or diseased arteries, which adds time and risk to the procedure. For these reasons, alternate access sites are sometimes employed. These include the radial, brachial and axillary arteries. However, these access sites are not always ideal, as they involve smaller arteries and may also include tortuous segments and some distance between the access and target sites.
Some Exemplary Issues with Current Technology
In some instances, a desired access site is the carotid artery. For example, procedures to treat disease at the carotid artery bifurcation and internal carotid artery are quite close to this access site. Procedures in the intracranial and cerebral arteries are likewise much closure to this access site than the femoral artery. This artery is also larger than some of the alternate access arteries noted above. (The common carotid artery is typically 6 to 10 mm in diameter, the radial artery is 2 to 3 mm in diameter.)
Because most access devices used in interventional procedure are designed for the femoral access, these devices are not ideal for the alternate carotid access sites, both in length and mechanical properties. This makes the procedure more cumbersome and in some cases more risky if using devices designed for femoral access in a carotid access procedure. For example, in some procedures it is desirable to keep the distal tip of the access sheath below or away from the carotid bifurcation, for example in procedures involving placing a stent at the carotid bifurcation. For patients with a low bifurcation, a short neck, or a very deep carotid artery, the angle of entry of the sheath into the artery (relative to the longitudinal axis of the artery) is very acute with respect to the longitudinal axis of the artery, i.e. more perpendicular than parallel relative to the longitudinal axis of the artery. This acute angle increases the difficulty and risk in sheath insertion and in insertion of devices through the sheath. In these procedures, there is also risk of the sheath dislodgement as only a minimal length of sheath can be inserted. In femoral or radial access cases, the sheaths are typically inserted into the artery all the way to the hub of the sheath, making sheath position very secure and parallel to the artery, so that the issues with steep insertion angle and sheath dislodgement do not occur in femoral access sites.
In other procedures, it is desirable to position the sheath tip up to and possibly including the petrous portion of the internal carotid artery, for example in procedures requiring access to cerebral vessels. Conventional interventional sheaths and sheath dilators are not flexible enough to be safely positioned at this site.
In addition, radiation exposure may be a problem for the hands of the operators for procedures utilizing a transcarotid access site, if the working areas are close to the access site.
What is needed is a system of devices that optimize ease and safety of arterial access directly into the common carotid artery. What is also needed is a system of devices which minimize radiation exposure to the operator. What are also needed are methods for safe and easy access into the carotid artery to perform peripheral and neurovascular interventional procedures.
Disclosed are methods and devices that enable safe, rapid and relatively short and straight transcarotid access to the arterial vasculature to treat coronary, peripheral and neurovascular disease states. The devices and associated methods include transcarotid access devices, guide catheters, catheters, and guide wires specifically to reach a target anatomy via a transcarotid access site. Included in this disclosure are kits of various combinations of these devices to facilitate multiple types of transcarotid interventional procedures.
In one aspect, there is disclosed a system of devices for accessing a carotid artery via a direct puncture of the carotid arterial wall, comprising a sheath guide wire, an arterial access sheath and a sheath dilator, wherein the arterial access sheath and sheath dilator are sized and configured to be inserted in combination over the sheath guide wire directly into the common carotid artery, and wherein the sheath has an internal lumen and a proximal port such that the lumen provides a passageway for an interventional device to be inserted via the proximal port into the carotid artery.
In another aspect, the system for accessing a carotid artery also includes: an access needle, an access guide wire, and an access cannula, all sized and configured to insert a sheath guide wire into the wall of the carotid artery so that the arterial access sheath and dilator may be placed either percutaneously or via a surgical cut down.
In another aspect, there is disclosed a method for treatment of coronary, peripheral or neurovascular disease, comprising: forming a penetration in a wall of a carotid artery; positioning an arterial access sheath through the penetration into the artery; and treating a target site using a treatment device.
In another aspect, there is disclosed an arterial access sheath for introducing an interventional device into an artery. The arterial access sheath includes an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck and an internal lumen in the elongated body having a proximal opening in a proximal region of the elongated body and a distal opening in a distal region of the elongated body. The internal lumen provides a passageway for introducing an interventional device into the common carotid artery when the elongated body is positioned in the common carotid artery. The elongated body has a proximal section and a distalmost section that is more flexible than the proximal section. A ratio of an entire length of the distalmost section to an overall length of the sheath body is one tenth to one half the overall length of the sheath body.
Other features and advantages should be apparent from the following description of various embodiments, which illustrate, by way of example, the principles of the invention.
b show embodiments of an arterial access sheath.
Disclosed are methods, systems, and devices for accessing and treating the vasculature via a transcarotid access point in the region of the carotid artery.
As shown in
Upon establishment of access to the carotid artery using the initial access system 100, an access sheath may be inserted into the carotid artery at the access site wherein the access sheath may be part of a transcarotid access sheath system.
In an embodiment, some or all of the components of transcarotid initial access system 100 and the transcarotid access sheath system 200 may be combined into one transcarotid access system kit such as by combining the components into a single, package, container or a collection of containers that are bundled together.
Arterial Access Sheath
With reference again to
The elongated sheath body 222 of the arterial access sheath 220 has a diameter that is suitable or particularly optimized to provide arterial access to the carotid artery. In an embodiment, the elongated sheath body 222 is in a size range from 5 to 9 French, or alternately in an inner diameter range from 0.072 inches to 0.126 inches. In an embodiment, the elongated sheath body 222 is a 6 or 7 French sheath. In an embodiment where the sheath is also used for aspiration or reverse flow, or to introduce larger devices, the sheath is an 8 French sheath.
The elongated sheath body 222 of the arterial access sheath 220 has a length from the proximal adapter 224 to a distal tip of the elongated sheath body 222 that is suitable for reaching treatment sites located in or toward the brain relative to an arterial access site in the common carotid artery CCA. For example, to access a carotid artery bifurcation or proximal internal carotid artery ICA from a CCA access site, the elongated sheath body 222 (i.e., the portion that can be inserted into the artery) of the access sheath 220 may have a length in a range from 7 to 15 cm. In an embodiment, the elongated sheath body 222 has a length in the range of 10-12 cm. For access to a same target site from a femoral access site, typical access sheaths must be between 80 and 110 cm, or a guide catheter must be inserted through an arterial access sheath and advanced to the target site. A guide catheter through an access sheath takes up luminal area and thus restricts the size of devices that may be introduced to the target site. Thus an access sheath that allows interventional devices to reach a target site without a guide catheter has advantages over an access sheath that requires use of a guide catheter to allow interventional devices to the target site.
Alternately, to position the distal tip of the elongated sheath body 222 more distally relative to the access site, for example to perform an intracranial or neurovascular procedure from a CCA access site, the elongated sheath body 222 of the access sheath 220 may have a length in the range from 10 cm to 30 cm, depending on the desired target position of the sheath distal tip. For example, if the target position is the distal CCA or proximal ICA, the elongated sheath body 222 may be in the range from 10 cm to 15 cm. If the desired target position is the mid to distal cervical, petrous, or cavernous segments of the ICA, the elongated sheath body 222 may be in the range from 15 to 30 cm.
Alternately, the arterial access sheath 220 is configured or adapted for treatment sites or target locations located proximal to the arterial access site (i.e. towards the aorta) when the access site is in the common carotid artery. For example the treatment site may be the proximal region of the CCA, CCA ostium, ascending or descending aorta or aortic arch, aortic valve, coronary arteries, or other peripheral arteries. For these target locations, the appropriate length of the elongated sheath body 222 depends on the distance from the target location to the access site. In this configuration, the elongated sheath body 222 is placed through an arterial access site and directed inferiorly towards the aorta.
The access sheath 220 may also include a radiopaque tip marker 230. In an example the radiopaque tip marker is a metal band, for example platinum iridium alloy, embedded near the distal end of the sheath body 222 of the access sheath 220. Alternately, the access sheath tip material may be a separate radiopaque material, for example a barium polymer or tungsten polymer blend. The sheath tip itself is configured such that when the access sheath 220 is assembled with the sheath dilator 260 to form a sheath assembly, the sheath assembly can be inserted smoothly over the sheath guide wire 300 through the arterial puncture with minimal resistance. In an embodiment, the elongated sheath body 222 of the access sheath 220 has a lubricious or hydrophilic coating to reduce friction during insertion into the artery. In an embodiment, the distal coating is limited to the distalmost 0.5 to 3 cm of the elongated sheath body 222, so that it facilitates insertion without compromising security of the sheath in the puncture site or the ability of the operator to firmly grasp the sheath during insertion. In an alternate embodiment, the sheath has no coating.
With reference to
For a sheath adapted to be inserted into the common carotid artery for the purpose of access to the carotid bifurcation, the length of the elongated sheath body 222 can be in the range from 7 to 15 cm, usually being from 10 cm to 12 cm. The inner diameter is typically in the range from 5 Fr (1 Fr=0.33 mm), to 10 Fr, usually being 6 to 8 Fr. For a sheath adapted to be inserted via the common carotid artery to the mid or distal internal carotid artery for the purpose of access to the intracranial or cerebral vessels, the length of the elongated sheath body 222 can be in the range from 10 to 30 cm, usually being from 15 cm to 25 cm. The inner diameter is typically in the range from 5 Fr (1 Fr=0.33 mm), to 10 Fr, usually being 5 to 6 Fr.
Particularly when the sheath is being introduced through the transcarotid approach, above the clavicle but below the carotid bifurcation, it is desirable that the elongated sheath body 222 be flexible while retaining hoop strength to resist kinking or buckling. This is especially important in procedures that have limited amount of sheath insertion into the artery, and there is a steep angle of insertion as with a transcarotid access in a patient with a deep carotid artery and/or with a short neck. In these instances, there is a tendency for the sheath body tip to be directed towards the back wall of the artery due to the stiffness of the sheath. This causes a risk of injury from insertion of the sheath body itself, or from devices being inserted through the sheath into the arteries, such as guide wires. Alternately, the distal region of the sheath body may be placed in a distal carotid artery which includes one or more bends, such as the petrous ICA. Thus, it is desirable to construct the sheath body 222 such that it can be flexed when inserted in the artery, while not kinking. In an embodiment, the sheath body 222 is circumferentially reinforced, such as by stainless steel or nitinol braid, helical ribbon, helical wire, cut stainless steel or nitinol hypotube, cut rigid polymer, or the like, and an inner liner so that the reinforcement structure is sandwiched between an outer jacket layer and the inner liner. The inner liner may be a low friction material such as PTFE. The outer jacket may be one or more of a group of materials including Pebax, thermoplastic polyurethane, or nylon.
In an embodiment, the sheath body 222 may vary in flexibility over its length. This change in flexibility may be achieved by various methods. For example, the outer jacket may change in durometer and/or material at various sections. Alternately, the reinforcement structure or the materials may change over the length of the sheath body. In one embodiment, there is a distalmost section of sheath body 222 which is more flexible than the remainder of the sheath body. For example, the flexural stiffness of the distalmost section is one third to one tenth the flexural stiffness of the remainder of the sheath body 222. In an embodiment, the distalmost section has a flexural stiffness (E*I) in the range 50 to 300 N-mm2 and the remaining portion of the sheath body 222 has a flexural stiffness in the range 500 to 1500 N-mm2, where E is the elastic modulus and I is the area moment of inertia of the device. For a sheath configured for a CCA access site, the flexible, distal most section comprises a significant portion of the sheath body 222 which may be expressed as a ratio. In an embodiment, the ratio of length of the flexible, distalmost section to the overall length of the sheath body 222 is at least one tenth and at most one half the length of the entire sheath body 222.
In some instances, the arterial access sheath is configured to access a carotid artery bifurcation or proximal internal carotid artery ICA from a CCA access site. In this instance, an embodiment of the sheath body 222 has a distalmost section 223 which is 3 to 4 cm and the overall sheath body 222 is 10 to 12 cm. In this embodiment, the ratio of length of the flexible, distalmost section to the overall length of the sheath body 222 is about one forth to one half the overall length of the sheath body 222. In another embodiment, there is a transition section 225 between the distalmost flexible section and the proximal section 231, with one or more sections of varying flexibilities between the distalmost section and the remainder of the sheath body. In this embodiment, the distalmost section is 2 to 4 cm, the transition section is 1 to 2 cm and the overall sheath body 222 is 10 to 12 cm, or expressed as a ratio, the distalmost flexible section and the transition section collectively form at least one fourth and at most one half the entire length of the sheath body.
In some instances, the sheath body 222 of the arterial access sheath is configured to be inserted more distally into the internal carotid artery relative to the arterial access location, and possibly into the intracranial section of the internal carotid artery. For example, a distalmost section 223 of the elongated sheath body 222 is 2.5 to 5 cm and the overall sheath body 222 is 20 to 30 cm in length. In this embodiment, the ratio of length of the flexible, distalmost section to the overall length of the sheath body is one tenth to one quarter of the entire sheath body 222. In another embodiment, there is a transition section 225 between the distalmost flexible section and the proximal section 231, in which the distalmost section is 2.5 to 5 cm, the transition section is 2 to 10 cm and the overall sheath body 222 is 20 to 30 cm. In this embodiment, the distalmost flexible section and the transition section collectively form at least one sixth and at most one half the entire length of the sheath body.
Other embodiments are adapted to reduce, minimize or eliminate a risk of injury to the artery caused by the distal-most sheath tip facing and contacting the posterior arterial wall. In some embodiments, the sheath has a structure configured to center the sheath body tip in the lumen of the artery such that the longitudinal axis of the distal region of the sheath body is generally parallel with the longitudinal or center axis of the lumen of the vessel. In an embodiment shown in
In another embodiment, the sheath alignment feature is one or more mechanical structures on the sheath body that can be actuated to extend outward from the sheath tip. In an embodiment, the sheath body 222 is configured to be inserted into the artery such that a particular edge of the arterial access is against the posterior wall of the artery. In this embodiment, the sheath alignment feature need only extend outward from one direction relative to the longitudinal axis of the sheath body 222 to lift or push the sheath tip away from the posterior arterial wall. For example, as shown in
In another embodiment, at least a portion of the sheath body 222 is pre-shaped so that after sheath insertion the tip is more aligned with the long axis of the vessel, even at a steep sheath insertion angle. In this embodiment the sheath body is generally straight when the dilator is assembled with the sheath during sheath insertion over the sheath guide wire, but once the dilator and guidewire are removed, the distalmost section of the sheath body assumes a curved or angled shape. In an embodiment, the sheath body is shaped such that the distalmost 0.5 to 1 cm section is angled from 10 to 30 degrees, as measured from the main axis of the sheath body, with a radius of curvature about 0.5″. To retain the curved or angled shape of the sheath body after having been straighten during insertion, the sheath may be heat set in the angled or curved shape during manufacture. Alternately, the reinforcement structure may be constructed out of nitinol and heat shaped into the curved or angled shape during manufacture. Alternately, an additional spring element may be added to the sheath body, for example a strip of spring steel or nitinol, with the correct shape, added to the reinforcement layer of the sheath.
In an alternate embodiment, there are procedures in which it is desirable to minimize flow resistance through the access sheath such as described in U.S. Pat. No. 7,998,104 to Chang and U.S. Pat. No. 8,157,760 to Criado, which are both incorporated by reference herein.
In some instances it is desirable for the sheath body 222 to also be able to occlude the artery in which it is positioned, for examples in procedures that may create distal emboli. In these cases, occluding the artery stops antegrade blood flow in the artery and thereby reduces the risk of distal emboli that may lead to neurologic symptoms such as TIA or stroke.
In some instances it is desirable to move the hemostasis valve away from the distal tip of the sheath, while maintaining the length of the insertable sheath body 222 of the sheath. This embodiment is configured to move the hands of the operator, and in fact his or her entire body, away from the target site and therefore from the image intensifier that is used to image the target site fluoroscopically, thus reducing the radiation exposure to the user during the procedure. Essentially, this lengthens the portion of the arterial access sheath 220 that is outside the body. This portion can be a larger inner and outer diameter than the sheath body 222. In instances where the outer diameter of the catheter being inserted into the sheath is close to the inner diameter of the sheath body, the annular space of the lumen that is available for flow is restrictive. Minimizing the sheath body length is thus advantageous to minimize this resistance to flow, such as during flushing of the sheath with saline or contrast solution, or during aspiration or reverse flow out of the sheath. In an embodiment, as shown in
Typically, vessel closure devices requires an arterial access sheath with a maximum distance of about 15 cm between distal tip of the sheath body to the proximal aspect of the hemostasis valve, with sheath body 222 of about 11 cm and the remaining 4 cm comprising the length of the proximal hemostasis valve; thus if the access sheath has a distance of greater than 15 cm it is desirable to remove the proximal extension 905 at the end of the procedure. In an embodiment, the proximal extension 905 is removable in such a way that after removal, hemostasis is maintained. For example a hemostasis valve is built into the connector 915 between the sheath body 222 and the proximal extension 905. The hemostasis valve is opened when the proximal extension 905 is attached to allow fluid communication and insertion of devices, but prevents blood flowing out of the sheath when the proximal extension 905 is removed. After the procedure is completed, the proximal extension 905 can be removed, reducing the distance between the proximal aspect of the hemostasis valve and sheath tip from greater than 15 cm to equal or less than 15 cm and thus allowing a vessel closure device to be used with the access sheath 220 to close the access site.
In some procedures it may be desirable to have a low resistance (large bore) flow line or shunt connected to the access sheath, such as described in U.S. Pat. No. 7,998,104 to Chang and U.S. Pat. No. 8,157,760 to Criado, which are both incorporated by reference herein. The arterial sheath embodiment shown in
In some procedures, it may be desirable to limit the amount of sheath body insertion into the artery, for example in procedures where the target area is very close to the arterial access site. In a stent procedure of the carotid artery bifurcation, for example, the sheath tip should be positioned proximal of the treatment site (relative to the access location) so that it does not interfere with stent deployment or enter the diseased area and possibly cause emboli to get knocked loose. In an embodiment of arterial sheath 220 shown in
In situations where the insertion of the sheath body is limited to between 2 and 3 cm, and particularly when the sheath body is inserted at a steep angle, the sheath may conform to a bayonet shape when secured to the patient. For example, the bayonet shape may comprise a first portion that extends along a first axis and a second portion that extends along a second axis that is axially offset from the first axis and/or non-parallel to the first axis. The springiness of the sheath body causes this shape to exert a force on the vessel at the site of insertion and increase the tendency of the sheath to come out of the vessel if not properly secured. To reduce the stress on the vessel, the sheath stopper may be pre-shaped into a curved or bayonet shape so that the stress of the sheath body when curved is imparted onto the sheath stopper rather than on the vessel. The sheath stopper may be made from springy but bendable material or include a spring element such as a stainless steel or nitinol wire or strip, so that when the dilator is inserted into the sheath and sheath stopper assembly, the sheath is relatively straight, but when the dilator is removed the sheath stopper assumes the pre-curved shape to reduce the force the sheath imparts on the vessel wall. Alternately, the sheath stopper may be made of malleable material or include a malleable element such as a bendable metal wire or strip, so that it can be shaped after the sheath is inserted into a desired curvature, again to reduce the stress the sheath imparts on the vessel wall.
Sheath Dilator
With reference again to
For a transcarotid access sheath system 200, it may be desirable to make the distal section of the sheath dilator 260 more flexible, to correspond with an increased flexible section of the access sheath 220. For example, the distal 2 to 5 cm of the sheath dilator 260 may be 20 to 50% more flexible than the proximal portion of the sheath dilator 260. This embodiment would allow a sheath and dilator being inserted to accommodate a steep insertion angle, as is often the case in a transcarotid access procedure, with a smoother insertion over the guidewire while still maintaining columnar support of the dilator. The columnar support is desirable to provide the insertion force required to dilate the puncture site and insert the access sheath.
For some transcarotid access sheath systems, it may be desirable to also use a smaller diameter access guidewire (for example in the range 0.014″ to 0.018″ diameter) to guide the sheath and dilator into the artery. In this embodiment, the sheath dilator tapered end 268 is configured to provide a smooth transition from a smaller wire size to the access sheath. In one variation, the sheath guide wire is 0.018″ and the inner dilator lumen is in the range 0.020″-0.022″. In another variation, the sheath guide wire is 0.014″ and the inner dilator lumen is in the range 0.016″ to 0.018″. The taper is similarly modified, for example the taper length is longer to accommodate a taper from a smaller diameter to the inner diameter of the access sheath, or may comprise two taper angles to provide a smooth transition from the smaller diameter wire to the access sheath without overly lengthening the overall length of the taper.
In some procedures, it is desirable to position the distal tip of the sheath body 222 of the arterial access sheath 220 in the mid to distal cervical, petrous, or cavernous segments of the ICA as described above. These segments have curvature often greater than 90 degrees. In may be desirable to have a sheath dilator with a softer and longer taper, to be able to navigate these bends easily without risk of injury to the arteries. However, in order to insert the sheath through the arterial puncture, the dilator desirably has a certain stiffness and taper to provide the dilating force. In an embodiment, the transcarotid access sheath system 200 is supplied or included in a kit that includes two or more tapered dilators 260A and 260B. The first tapered dilator 260A is used with the arterial access device to gain entry into the artery, and is thus sized and constructed in a manner similar to standard introducer sheath dilators. Example materials that may be used for the tapered dilator include, for example, high density polyethylene, 72D Pebax, 90D Pebax, or equivalent stiffness and lubricity material. A second tapered dilator 260B of the kit may be supplied with the arterial access device with a softer distal section or a distal section that has a lower bending stiffness relative to the distal section of the first tapered dilator. That is, the second dilator has a distal region that is softer, more flexible, or articulates or bends more easily than a corresponding distal region of the first dilator. The distal region of the second dilator thus bends more easily than the corresponding distal region of the first dilator. In an embodiment, the distal section of the first dilator 260A has a bending stiffness in the range of 50 to 100 N-mm2 and the distal section of the second dilator 260B has a bending stiffness in the range of 5 to 15 N-mm2.
The second dilator 260B (which has a distal section with a lower bending stiffness) may be exchanged with the initial, first dilator such that the arterial access device may be inserted into the internal carotid artery and around curvature in the artery without undue force or trauma on the vessel due to the softer distal section of the second dilator. The distal section of the soft, second dilator may be, for example, 35 or 40D Pebax, with a proximal portion made of, for example 72D Pebax. An intermediate mid portion or portions may be included on the second dilator to provide a smooth transition between the soft distal section and the stiffer proximal section. In an embodiment, one or both dilators may have radiopaque tip markers so that the dilator tip position is visible on fluoroscopy. In one variation, the radiopaque marker is a section of tungsten loaded Pebax or polyurethane which is heat welded to the distal tip of the dilator. Other radiopaque materials may similarly be used to create a radiopaque marker at the distal tip.
To facilitate exchange of the first dilator for the second dilator, one or both dilators may be configured such that the distal section of the dilator is constructed from a tapered single-lumen tube, but the proximal portion of the dilator and any adaptor on the proximal end has a side opening.
A method of use of this embodiment of an access sheath kit is now described. A sheath guide wire, such as an 0.035″ guidewire, is inserted into the common carotid artery, either using a Modified Seldinger technique or a micropuncture technique. The distal end of the guidewire can be positioned into the internal or external carotid artery, or stop in the common carotid artery short of the bifurcation. The arterial access sheath with the first, stiffer dilator, is inserted over the 0.035″ wire into the artery. The arterial access sheath is inserted such that at least 2.5 cm of sheath body 222 is in the artery. If additional purchase is desired, the arterial access sheath may be directed further, and into the internal carotid artery. The first dilator is removed while keeping both the arterial access sheath and the 0.035″ wire in place. The side opening 1215 in the proximal portion of the dilator allows the dilator to be removed in a “rapid exchange” fashion such that most of the guidewire outside the access device may be grasped directly during dilator removal. The second dilator is then loaded on to the 0.035″ wire and inserted into the sheath. Again, a dilator with a side opening 1215 in the proximal portion of the dilator may be used to allow the 0.035″ wire to be grasped directly during guide wire insertion in a “rapid exchange” technique. Once the second dilator is fully inserted into the arterial access device, the arterial access sheath with the softer tipped, second dilator is advanced up the internal carotid artery and around bends in the artery without undue force or concern for vessel trauma. This configuration allows a more distal placement of the arterial access sheath without compromising the ability of the device to be inserted into the artery.
Alternately, one or more standard dilators may be used without side openings. If a standard dilator without a side opening is used, after the access device is inserted into the artery over a guide wire with the first dilator, the first dilator may be removed together with the guidewire, leaving only the access device in place. The second dilator with a guide wire preloaded into the central lumen may be inserted together into the arterial access device. Once fully inserted, the access device and second dilator with softer tip may be advanced distally up the internal carotid artery as above. In this alternate method, the initial guide wire may be used with both dilators, or may be exchanged for a softer tipped guide wire when inserted with the second softer tipped dilator.
In some instances, it may be desirable to insert the access sheath system over an 0.035″ wire into the carotid artery, but then exchange the wire to a smaller guidewire, in the range 0.014″ to 0.018″. Because the access into the carotid artery may require a steep angle of entry, a wire that can offer good support such as an 0.035″ wire may be desirable to initially introduce the access sheath into the CCA. However, once the sheath is in the artery but the user would like to advance it further over a smaller guidewire, it may be desirable to exchange the 0.035″ wire for a smaller guide wire. Alternately, the user may exchange both the dilator and 0.035″ wire for a softer dilator and smaller guide wire in the range 0.014″ to 0.018″. Alternately, the user may wish to position an 0.014″ guidewire which he or she will subsequently to introduce an interventional device, while the sheath and dilator are still in place. The dilator may offer access and support for this guide wire, and in instances of severe access sheath angle may aid in directing the wire away from the posterior wall of the artery so that the wire may be safely advanced into the vascular lumen without risk of luminal injury.
In an embodiment as shown in
An alternate embodiment, shown in
Sheath Guidewire
Arterial access sheaths are typically introduced into the artery over a sheath guidewire of 0.035″ or 0.038″ diameter. The inner diameter and taper length of the distal tip of the dilator are sized to fit with such a guidewire. Some sheaths, for example for radial artery access, are sized to accommodate a sheath guidewire of 0.018″ diameter, with a corresponding dilator having a distal tip inner diameter and taper length. The sheath guidewire may have an atraumatic straight, angled, or J-tip. The guidewire smoothly transitions to a stiffer segment on the proximal end. This configuration allows atraumatic entry and advancement of the wire into the artery while allowing support for the sheath when the sheath is introduced into the artery over the wire. Typically the transition from the atraumatic tip is about 4 to 9 cm to the stiffer section. The sheath is usually inserted 15 to 20 cm into the artery, so that the stiffer segment of the wire is at the arterial entry site when the sheath is being inserted.
However, in the case of a transcarotid access entry point, the amount of wire that can be inserted is much less than 15 cm before potentially causing harm to the distal vessels. In a case of a transcarotid access for a carotid stent or PTA procedure, it is very important that the wire insertion length is limited, to avoid risk of distal emboli being generated by the sheath guide wire at the site of carotid artery disease. Thus it is desirable to provide a guide wire that is able to provide support for a potentially steep sheath entry angle while being limited in length of insertion. In an embodiment, a transcarotid sheath guidewire has an atraumatic tip section but have a very distal and short transition to a stiffer section. For example, the soft tip section is 1.5 to 2.5 cm, followed by a transition section with length from 3 to 5 cm, followed by a stiffer proximal segment, with the stiffer proximal section comprising the remainder of the wire.
The sheath guidewire may have guide wire markings 318 to help the user determine where the tip of the wire is with respect to the dilator. For example, there may be a marking on the proximal end of the wire corresponding to when the tip of the wire is about to exit the micro access cannula tip. This marking would provide rapid wire position feedback to help the user limit the amount of wire insertion. In another embodiment, the wire may include an additional mark to let the user know the wire has existed the cannula by a set distance, for example 5 cm.
Micro Access Components
With reference to
Similarly to sheath guide wires, micro access guide wires have a transition segment from a floppy distal tip to a core section that is stiffer than the distal tip or distal region. Such micro access guidewires are typically 0.018″ in diameter, with a floppy, distal segment of about 1-2 cm, and a transition zone of 5-6 cm to the stiffer segment. In an embodiment, a transcarotid access guidewire is from 0.014″ to 0.018″ in diameter, and has a floppy segment of 1 cm, a transition zone of 2-3 cm to bring the stiff supportive section much closer to the distal tip. This will allow the user to have good support for his micro access cannula insertion even in steep access angles and limitations on wire insertion length.
As with the sheath guide wire, the micro access guide wire may have guide wire markings 143 to help the user determine where the tip of the wire is with respect to the micro cannula. For example, a marking can be located on the proximal end of the wire corresponding to when the tip of the wire is about to exit the micro cannula. This marking would provide rapid wire position feedback to help the user limit the amount of wire insertion. In another embodiment, the wire may include an additional mark to let the user know the wire has existed the dilator by a set distance, for example 5 cm.
The micro access cannula itself may be configured for transcarotid insertion. Typically, the micro access cannula 160 includes a cannula 162 and an inner dilator 168 with a tapered tip. The inner dilator 168 provides a smooth transition between the cannula and the access guide wire. The cannula is sized to receive the 0.035″ wire, with inner diameter in the range 0.038″ to 0.042″. In an embodiment, a micro access cannula 160 is configured for transcarotid access. For example the dilator of the cannula may be sized for a smaller 0.014″ access guide wire 140. Additionally, the cannula itself may have depth marking to aid the user in limiting the amount of insertion. In an embodiment, the micro access cannula 160 has a radiopaque marker 164 at the distal tip of the cannula 162 to help the user visualize the tip location under fluoroscopy. This is useful for example in cases where the user may want to position the cannula in the ICA or ECA, for example.
Exemplary Kits:
Any or all of the devices described above may be provided in kit form to the user such that one or more of the components of the systems are included in a common package or collection of packages. An embodiment of an access sheath kit comprises an access sheath, sheath dilator, and sheath guidewire all configured for transcarotid access as described above.
In an embodiment, a micro access kit comprises an access needle, a micro access guide wire, and a micro access cannula and dilator wherein the guidewire is 0.014″ and the micro access cannula and dilator are sized to be compatible with the 0.014″ guide wire.
In an embodiment, an access kit comprises the access sheath, sheath dilator, sheath guide wire, access needle, micro access guide wire and micro access cannula and dilator, all configured for transcarotid access.
In an alternate embodiment, the access guidewire is also used as the sheath guide wire. In this embodiment, the access kit comprises an access needle, access guide wire, access sheath and dilator. The sheath and dilator use the access guide wire to be inserted into the vessel, thereby avoiding the steps required to exchange up to a larger sheath guidewire. In this embodiment, the dilator taper length and inner lumen is sized to be compatible with the smaller access guide wire. In one embodiment the access guide wire is 0.018″. In an alternate embodiment the access guide wire is 0.016″. In an alternate embodiment, the access guide wire is 0.014″.
Exemplary Methods:
There are now described exemplary methods of use for a transcarotid access system. In an exemplary transcarotid procedure to treat a carotid artery stenosis, the user starts by performing a cut down to the common carotid artery. The user then inserts an access needle 120 into the common carotid artery at the desired access site. An access guide wire 140 with a taper configured for transcarotid access is inserted through the needle into the common carotid artery and advanced into the CCA. The access needle 120 is removed and a micro access cannula 160 is inserted over the wire 140 into the CCA. The micro access cannula is inserted a desired depth using the marks 166 on the cannula as a guide, to prevent over insertion.
The user removes the cannula inner dilator 168 and guide wire 140, leaving the cannula 162 in place. If desired, the user performs an angiogram through the cannula 162. The user then places sheath guide wire 300 through the cannula, using guide wire markings 318 to aid in inserting the wire to a desired insertion length. The cannula 162 is removed from the guidewire and the access sheath 220 and sheath dilator 260 are inserted as an assembly over the sheath guidewire 300 into the CCA. The sheath stopper flange 1115 of the sheath stopper 1105 limits the insertion length of the arterial sheath. Once positioned, the dilator 260 and guidewire 300 are removed. The sheath is then sutured to the patient using the securing eyelets 234 and/or ribs 236. An interventional procedure is then performed by introduction of interventional devices through hemostasis valve 226 on the proximal end of the arterial sheath and to the desire treatment site. Contrast injections may be made as desired during the procedure via the flush arm 228 on the arterial sheath 220.
Alternately, the sheath guidewire 300 is placed into the CCA via a single needle puncture with a larger access needle, for example an 18G needle. In this embodiment, the access cannula and access guide wire are not needed. This embodiment reduces the number of steps required to access the artery, and in some circumstances may be desirable to the user.
Alternately, the sheath dilator is a two-part sheath dilator assembly 260 as shown in
In an alternate embodiment, the sheath dilator is a two lumen sheath dilator 1705. In this embodiment, the sheath and dilator are inserted over the sheath guide wire 300, with the sheath guidewire positioned in the larger lumen 1805 of dilator 1705. Once the sheath and dilator is in place, an interventional 0.014″ guide wire is positioned through the smaller lumen 1815. The dilator provides distal support and maintains the position of the sheath tip in the axial direction of the vessel lumen, thus allowing a potentially safer and easier advancement of the 0.014″ wire than if the dilator were removed and the sheath tip was directed at least partially towards to posterior wall of the artery. Once the 0.014″ wire is positioned at or across the target treatment site, the sheath dilator 1705 and sheath guide wire 0.035″ are then removed, and the intervention proceeds.
In yet another embodiment, it may be desirable to occlude the CCA during the intervention to minimize antegrade flow of emboli. In this embodiment, the occlusion step may be performed via vascular surgical means such as with a vessel loop, tourniquet, or vascular clamp. In an alternate embodiment, the access sheath 220 has an occlusion element such as an occlusion balloon 250 on the distal tip. In this embodiment, the balloon is inflated when CCA occlusion is desired. In a further variant, while the CCA is occluded either surgically or via balloon occlusion, it may be desirable to connect the arterial sheath to a flow shunt, for example to create a reverse flow system around the area of the treatment site to minimize distal emboli. In this embodiment, the arterial sheath 220 has a Y connection to a flow line 256. The flow line may be connected to a return site with a pressure lower than arterial pressure to create a pressure gradient that results in reverse flow through the shunt, for example an external reservoir or a central venous return site like the femoral vein or the internal jugular vein. Alternately, the flow line may be connected to an aspiration source such as an aspiration pump or syringe.
In another embodiment, a transcarotid access system is used to perform a percutaneous neurointerventional procedure. In this embodiment, the user performs a percutaneous puncture of the common carotid artery CCA with an access needle 120 at the desired access site. Ultrasound may be used to accurately identify a suitable access site and guide the needle puncture. An access guide wire 140 is inserted through the needle into the common carotid artery and advanced into the CCA. The access needle 120 is removed and a micro access cannula 160 is inserted over the wire 140 into the CCA. The user removes the cannula inner dilator 168 and guide wire 140, leaving the cannula 162 in place. If desired, the user performs an angiogram through the cannula 162. The user then places sheath guide wire 300 through the cannula, using guide wire markings 318 to aid in desired insertion length. The cannula 162 is removed from the guidewire and the access sheath 220 and sheath dilator 260 are inserted as an assembly over the sheath guidewire 300 into the CCA.
Alternately, the smaller access guide wire 140 is used to position the access sheath 220 and sheath dilator 260 into the CCA. In this embodiment, the sheath dilator tapered tip 266 has been configured to transition smoothly from the access guide wire 140 to the access sheath 220. In one variant, the access needle is 21G and the access guide wire is 0.018″. In another variant, the access needle is 24G and the access guide wire is 0.014″. Once the sheath is placed, the guide wire and sheath dilator are removed and an interventional procedure is then performed by introduction of interventional devices through hemostasis valve 226 on the proximal end of the arterial sheath and to the desire treatment site. Contrast injections may be made as desired during the procedure via the flush arm 228 on the arterial sheath 220.
Alternately, it may be desirable once the sheath is placed in the CCA to advance it further into the ICA, for example in the mid to distal cervical ICA, petrous ICA or further distally. In this embodiment, the sheath dilator may be replaced with a softer sheath dilator so that the sheath may be advanced without risk of damaging the distal ICA. In this embodiment, the softer dilator has a distal radiopaque marker so that the user may easily visualize the leading edge of the sheath and dilator assembly during positioning of the sheath. Once the access sheath is positioned, the dilator and sheath guide wire may be removed and the intervention can proceed. Alternately, once the sheath is placed in the CCA, the 0.035″ guide wire may be removed and an inner dilator with a smaller guide wire in the range 0.014″ to 0.018″ may be inserted into sheath dilator. The sheath dilator assembly with the inner dilator and smaller guide wire may be then positioned more distally in the ICA with reduced risk of vessel trauma.
In an embodiment, it may be desirable to occlude the CCA or ICA during portions of the procedure to reduce the chance of distal emboli flowing to the brain. In this embodiment, the CCA or ICA is occluded by means of an occlusion balloon 250 on the access sheath 220. It may also be desireable to connect the arterial sheath to a flow shunt, for example to create a reverse flow system around the area of the treatment site to minimize distal emboli. In this embodiment, the arterial sheath 220 has a Y connection to a flow line 256. The flow line may be connected to a return site with a pressure lower than arterial pressure to create a pressure gradient that results in reverse flow through the shunt. Alternately, the flow line may be connected to an aspiration source such as an aspiration pump or syringe.
While this specification contains many specifics, these should not be construed as limitations on the scope of an invention that is claimed or of what may be claimed, but rather as descriptions of features specific to particular embodiments. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub-combination. Moreover, although features may be described above as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub-combination or a variation of a sub-combination. Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results.
Although embodiments of various methods and devices are described herein in detail with reference to certain versions, it should be appreciated that other versions, embodiments, methods of use, and combinations thereof are also possible. Therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.
This application is continuation of U.S. patent application Ser. No. 15/606,381 entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed May 26, 2017, issuing as U.S. Pat. No. 10,039,906 on Aug. 7, 2018, which claims priority to U.S. patent application Ser. No. 15/210,770 entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed Jul. 14, 2016, now U.S. Pat. No. 9,662,480, which is a continuation of U.S. patent application Ser. No. 15/005,770 entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed Jan. 25, 2016, now U.S. Pat. No. 9,399,118, which is a continuation of U.S. patent application Ser. No. 14/575,199 entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed Dec. 18, 2014, now U.S. Pat. No. 9,126,018, which is a continuation of U.S. patent application Ser. No. 14/537,316 entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed Nov. 10, 2014, now U.S. Pat. No. 9,241,699, which claims the benefit of priority to U.S. Provisional Application Ser. No. 62/046,112, entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed on Sep. 4, 2014, and U.S. Provisional Application Ser. No. 62/075,169, entitled “METHODS AND DEVICES FOR TRANSCAROTID ACCESS” filed on Nov. 4, 2014. Priority of the aforementioned filing dates is claimed and the patent applications are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3993079 | Henriques De Gatztanondo | Nov 1976 | A |
4354491 | Marbry | Oct 1982 | A |
4771777 | Horzewski et al. | Sep 1988 | A |
4840690 | Melinyshyn et al. | Jun 1989 | A |
4862891 | Smith | Sep 1989 | A |
4865581 | Lundquist et al. | Sep 1989 | A |
4921478 | Solano et al. | May 1990 | A |
4921479 | Grayzel | May 1990 | A |
4946440 | Hall | Aug 1990 | A |
5084022 | Claude | Jan 1992 | A |
5112308 | Olsen et al. | May 1992 | A |
5135484 | Wright | Aug 1992 | A |
5250060 | Carbo et al. | Oct 1993 | A |
5312356 | Engelson et al. | May 1994 | A |
RE34633 | Sos et al. | Jun 1994 | E |
5324262 | Fischell et al. | Jun 1994 | A |
5328471 | Slepian | Jul 1994 | A |
5380284 | Don Michael | Jan 1995 | A |
5429605 | Bernd et al. | Jul 1995 | A |
5437632 | Engelson | Aug 1995 | A |
5443454 | Tanabe et al. | Aug 1995 | A |
5454795 | Samson | Oct 1995 | A |
5456667 | Ham et al. | Oct 1995 | A |
5476450 | Ruggio | Dec 1995 | A |
5484412 | Pierpont | Jan 1996 | A |
5484418 | Quiachon et al. | Jan 1996 | A |
5492530 | Fischell et al. | Feb 1996 | A |
5496294 | Hergenrother et al. | Mar 1996 | A |
5522836 | Palermo | Jun 1996 | A |
5542937 | Chee et al. | Aug 1996 | A |
5558635 | Cannon | Sep 1996 | A |
5573520 | Schwartz et al. | Nov 1996 | A |
5599326 | Carter | Feb 1997 | A |
5628754 | Shevlin et al. | May 1997 | A |
5658264 | Samson | Aug 1997 | A |
5667499 | Welch et al. | Sep 1997 | A |
5695483 | Samson | Dec 1997 | A |
5702373 | Samson | Dec 1997 | A |
5707376 | Kavteladze et al. | Jan 1998 | A |
5730734 | Adams et al. | Mar 1998 | A |
5749849 | Engelson | May 1998 | A |
5749858 | Cramer | May 1998 | A |
5794629 | Frazee | Aug 1998 | A |
5795341 | Samson | Aug 1998 | A |
5810869 | Kaplan et al. | Sep 1998 | A |
5827229 | Auth et al. | Oct 1998 | A |
5833650 | Imran | Nov 1998 | A |
5836926 | Peterson et al. | Nov 1998 | A |
5836955 | Buelna et al. | Nov 1998 | A |
5846251 | Hart | Dec 1998 | A |
5851203 | van Muiden | Dec 1998 | A |
5851210 | Torossian | Dec 1998 | A |
5853400 | Samson | Dec 1998 | A |
5876367 | Kaganov et al. | Mar 1999 | A |
5876386 | Samson | Mar 1999 | A |
5882334 | Sepetka et al. | Mar 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5908407 | Frazee et al. | Jun 1999 | A |
5913848 | Luther et al. | Jun 1999 | A |
5916208 | Luther et al. | Jun 1999 | A |
5921952 | Desmond, III et al. | Jul 1999 | A |
5928192 | Maahs | Jul 1999 | A |
5935122 | Fourkas et al. | Aug 1999 | A |
5938645 | Gordon | Aug 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5964773 | Greenstein | Oct 1999 | A |
5976093 | Jang | Nov 1999 | A |
5976178 | Goldsteen et al. | Nov 1999 | A |
5997508 | Lunn et al. | Dec 1999 | A |
5997523 | Jang | Dec 1999 | A |
6004310 | Bardsley et al. | Dec 1999 | A |
6013085 | Howard | Jan 2000 | A |
6022336 | Zadno-Azizi et al. | Feb 2000 | A |
6022340 | Sepetka et al. | Feb 2000 | A |
6030369 | Engelson et al. | Feb 2000 | A |
6033388 | Nordstrom et al. | Mar 2000 | A |
6044845 | Lewis | Apr 2000 | A |
6053903 | Samson | Apr 2000 | A |
6053904 | Scribner et al. | Apr 2000 | A |
6071263 | Kirkman | Jun 2000 | A |
6074357 | Kaganov et al. | Jun 2000 | A |
6074398 | Leschinsky | Jun 2000 | A |
6090072 | Kratoska et al. | Jul 2000 | A |
6110139 | Loubser | Aug 2000 | A |
6139524 | Killion | Oct 2000 | A |
6146370 | Barbut | Nov 2000 | A |
6146373 | Cragg et al. | Nov 2000 | A |
6146415 | Fitz | Nov 2000 | A |
6152909 | Bagaoisan et al. | Nov 2000 | A |
6152912 | Jansen et al. | Nov 2000 | A |
6159230 | Samuels | Dec 2000 | A |
6161547 | Barbut | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6176844 | Lee | Jan 2001 | B1 |
6197016 | Fourkas et al. | Mar 2001 | B1 |
6206868 | Parodi | Mar 2001 | B1 |
6210370 | Chi-Sing et al. | Apr 2001 | B1 |
6234971 | Jang | May 2001 | B1 |
6238430 | Klumb et al. | May 2001 | B1 |
6254628 | Wallace et al. | Jul 2001 | B1 |
6258080 | Samson | Jul 2001 | B1 |
6270477 | Bagaoisan et al. | Aug 2001 | B1 |
6277139 | Levinson et al. | Aug 2001 | B1 |
6287319 | Aboul-Hosn et al. | Sep 2001 | B1 |
6295989 | Connors, II | Oct 2001 | B1 |
6295990 | Lewis et al. | Oct 2001 | B1 |
6306106 | Boyle | Oct 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6364900 | Heuser | Apr 2002 | B1 |
6368316 | Jansen et al. | Apr 2002 | B1 |
6368344 | Fitz | Apr 2002 | B1 |
6379325 | Benett et al. | Apr 2002 | B1 |
6383172 | Barbut | May 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6423032 | Parodi | Jul 2002 | B2 |
6423086 | Barbut et al. | Jul 2002 | B1 |
6428531 | Visuri et al. | Aug 2002 | B1 |
6435189 | Lewis et al. | Aug 2002 | B1 |
6436087 | Lewis et al. | Aug 2002 | B1 |
6454741 | Muni et al. | Sep 2002 | B1 |
6458151 | Saltiel | Oct 2002 | B1 |
6464664 | Jonkman et al. | Oct 2002 | B1 |
6481439 | Lewis et al. | Nov 2002 | B1 |
6482172 | Thramann | Nov 2002 | B1 |
6482217 | Pintor et al. | Nov 2002 | B1 |
6508824 | Flaherty et al. | Jan 2003 | B1 |
6517520 | Chang et al. | Feb 2003 | B2 |
6527746 | Oslund et al. | Mar 2003 | B1 |
6533800 | Barbut | Mar 2003 | B1 |
6540712 | Parodi et al. | Apr 2003 | B1 |
6544276 | Azizi | Apr 2003 | B1 |
6549800 | Atalar et al. | Apr 2003 | B1 |
6551268 | Kaganov et al. | Apr 2003 | B1 |
6555057 | Barbut et al. | Apr 2003 | B1 |
6562049 | Norlander et al. | May 2003 | B1 |
6562052 | Nobles et al. | May 2003 | B2 |
6582390 | Sanderson | Jun 2003 | B1 |
6582396 | Parodi | Jun 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6595953 | Coppi et al. | Jul 2003 | B1 |
6595980 | Barbut | Jul 2003 | B1 |
6605074 | Zadno-Azizi et al. | Aug 2003 | B2 |
6612999 | Brennan et al. | Sep 2003 | B2 |
6623471 | Barbut | Sep 2003 | B1 |
6623491 | Thompson | Sep 2003 | B2 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6626886 | Barbut | Sep 2003 | B1 |
6632236 | Hogendijk | Oct 2003 | B2 |
6635070 | Leeflang et al. | Oct 2003 | B2 |
6638243 | Kupiecki | Oct 2003 | B2 |
6638245 | Miller et al. | Oct 2003 | B2 |
6641573 | Parodi | Nov 2003 | B1 |
6645160 | Heesch | Nov 2003 | B1 |
6645222 | Parodi et al. | Nov 2003 | B1 |
6652480 | Imran et al. | Nov 2003 | B1 |
6656152 | Putz | Dec 2003 | B2 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6663652 | Daniel et al. | Dec 2003 | B2 |
6679893 | Tran | Jan 2004 | B1 |
6682505 | Bates et al. | Jan 2004 | B2 |
6685722 | Rosenbluth et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6711436 | Duhaylongsod | Mar 2004 | B1 |
6719717 | Johnson et al. | Apr 2004 | B1 |
6730104 | Sepetka et al. | May 2004 | B1 |
6733517 | Collins | May 2004 | B1 |
6749627 | Thompson et al. | Jun 2004 | B2 |
6755847 | Eskuri | Jun 2004 | B2 |
6758854 | Butler et al. | Jul 2004 | B1 |
6764464 | McGuckin, Jr. et al. | Jul 2004 | B2 |
6790204 | Zadno-Azizi et al. | Sep 2004 | B2 |
6824545 | Sepetka et al. | Nov 2004 | B2 |
6827730 | Leschinsky | Dec 2004 | B1 |
6837881 | Barbut | Jan 2005 | B1 |
6840949 | Barbut | Jan 2005 | B2 |
6849068 | Bagaoisan et al. | Feb 2005 | B1 |
6855136 | Dorros et al. | Feb 2005 | B2 |
6884235 | McGuckin, Jr. et al. | Apr 2005 | B2 |
6902540 | Dorros et al. | Jun 2005 | B2 |
6905490 | Parodi | Jun 2005 | B2 |
6905505 | Nash et al. | Jun 2005 | B2 |
6908474 | Hogendijk et al. | Jun 2005 | B2 |
6929632 | Nita et al. | Aug 2005 | B2 |
6929634 | Dorros et al. | Aug 2005 | B2 |
6936060 | Hogendijk et al. | Aug 2005 | B2 |
6958059 | Zadno-Azizi | Oct 2005 | B2 |
6960189 | Bates et al. | Nov 2005 | B2 |
6972030 | Lee et al. | Dec 2005 | B2 |
7001400 | Modesitt et al. | Feb 2006 | B1 |
7004924 | Brugger et al. | Feb 2006 | B1 |
7004931 | Hogendijk | Feb 2006 | B2 |
7004952 | Nobles et al. | Feb 2006 | B2 |
7022100 | Aboul-Hosn et al. | Apr 2006 | B1 |
7029488 | Schonholz et al. | Apr 2006 | B2 |
7033336 | Hogendijk | Apr 2006 | B2 |
7033344 | Imran | Apr 2006 | B2 |
7048758 | Boyle et al. | May 2006 | B2 |
7063714 | Dorros et al. | Jun 2006 | B2 |
7083594 | Coppi | Aug 2006 | B2 |
7104979 | Jansen et al. | Sep 2006 | B2 |
7108677 | Courtney et al. | Sep 2006 | B2 |
7144386 | Korkor et al. | Dec 2006 | B2 |
7150712 | Buehlmann et al. | Dec 2006 | B2 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7166088 | Heuser | Jan 2007 | B2 |
7169165 | Belef et al. | Jan 2007 | B2 |
7172621 | Theron | Feb 2007 | B2 |
7223253 | Hogendijk | May 2007 | B2 |
7232452 | Adams et al. | Jun 2007 | B2 |
7250042 | Kataishi et al. | Jul 2007 | B2 |
7306585 | Ross | Dec 2007 | B2 |
7309334 | von Hoffmann | Dec 2007 | B2 |
7367982 | Nash et al. | May 2008 | B2 |
7374560 | Ressemann et al. | May 2008 | B2 |
7374561 | Barbut | May 2008 | B2 |
7384412 | Coppi | Jun 2008 | B2 |
7402151 | Rosenman et al. | Jul 2008 | B2 |
7422579 | Wahr et al. | Sep 2008 | B2 |
7458980 | Barbut | Dec 2008 | B2 |
7497844 | Spear et al. | Mar 2009 | B2 |
7524303 | Don Michael et al. | Apr 2009 | B1 |
7534250 | Schaeffer et al. | May 2009 | B2 |
7731683 | Jang et al. | Jun 2010 | B2 |
7766049 | Miller et al. | Aug 2010 | B2 |
7766820 | Core | Aug 2010 | B2 |
7806906 | Don Michael | Oct 2010 | B2 |
7815626 | McFadden et al. | Oct 2010 | B1 |
7842065 | Belef et al. | Nov 2010 | B2 |
7867216 | Wahr et al. | Jan 2011 | B2 |
7905856 | McGuckin, Jr. et al. | Mar 2011 | B2 |
7905877 | Jimenez et al. | Mar 2011 | B1 |
7909812 | Jansen et al. | Mar 2011 | B2 |
7927309 | Palm | Apr 2011 | B2 |
7927347 | Hogendijk et al. | Apr 2011 | B2 |
7972308 | Putz | Jul 2011 | B2 |
7998104 | Chang | Aug 2011 | B2 |
8029533 | Bagaoisan et al. | Oct 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8142413 | Root et al. | Mar 2012 | B2 |
RE43300 | Saadat et al. | Apr 2012 | E |
8152782 | Jang et al. | Apr 2012 | B2 |
8157760 | Criado et al. | Apr 2012 | B2 |
8181324 | McFadden et al. | May 2012 | B2 |
8221348 | Hackett et al. | Jul 2012 | B2 |
8231600 | von Hoffmann | Jul 2012 | B2 |
8252010 | Raju et al. | Aug 2012 | B1 |
8292850 | Root et al. | Oct 2012 | B2 |
8343089 | Chang | Jan 2013 | B2 |
8414516 | Chang | Apr 2013 | B2 |
8545552 | Garrison et al. | Oct 2013 | B2 |
8574245 | Garrison et al. | Nov 2013 | B2 |
8870805 | Chang | Oct 2014 | B2 |
8961549 | Conn | Feb 2015 | B2 |
9126018 | Garrison | Sep 2015 | B1 |
9241699 | Kume et al. | Jan 2016 | B1 |
20010044598 | Parodi | Nov 2001 | A1 |
20010049486 | Evans et al. | Dec 2001 | A1 |
20010049517 | Zadno-Azizi et al. | Dec 2001 | A1 |
20020087119 | Parodi | Jul 2002 | A1 |
20020128679 | Turovskiy et al. | Sep 2002 | A1 |
20020133111 | Shadduck | Sep 2002 | A1 |
20020151922 | Hogendijk et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020156460 | Ye et al. | Oct 2002 | A1 |
20020165598 | Wahr et al. | Nov 2002 | A1 |
20020173815 | Hogendijk et al. | Nov 2002 | A1 |
20020183783 | Shadduck | Dec 2002 | A1 |
20030040762 | Dorros et al. | Feb 2003 | A1 |
20030065356 | Tsugita et al. | Apr 2003 | A1 |
20030069468 | Bolling et al. | Apr 2003 | A1 |
20030078562 | Makower et al. | Apr 2003 | A1 |
20030186203 | Aboud | Oct 2003 | A1 |
20030212304 | Lattouf | Nov 2003 | A1 |
20030212384 | Hayden | Nov 2003 | A1 |
20040059243 | Flores et al. | Mar 2004 | A1 |
20040116878 | Byrd et al. | Jun 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138608 | Barbut et al. | Jul 2004 | A1 |
20040181150 | Evans et al. | Sep 2004 | A1 |
20040210194 | Bonnette et al. | Oct 2004 | A1 |
20050004553 | Douk | Jan 2005 | A1 |
20050065467 | Pudelko et al. | Mar 2005 | A1 |
20050090802 | Connors et al. | Apr 2005 | A1 |
20050131453 | Parodi | Jun 2005 | A1 |
20050154344 | Chang | Jul 2005 | A1 |
20050154349 | Renz et al. | Jul 2005 | A1 |
20050209559 | Thornton et al. | Sep 2005 | A1 |
20050273051 | Coppi | Dec 2005 | A1 |
20060058836 | Bose et al. | Mar 2006 | A1 |
20060058837 | Bose et al. | Mar 2006 | A1 |
20060058838 | Bose et al. | Mar 2006 | A1 |
20060089618 | McFerran et al. | Apr 2006 | A1 |
20060106338 | Chang | May 2006 | A1 |
20060135961 | Rosenman et al. | Jun 2006 | A1 |
20060200191 | Zadno-Azizi | Sep 2006 | A1 |
20060271098 | Peacock | Nov 2006 | A1 |
20070021778 | Carly | Jan 2007 | A1 |
20070073264 | Stedman et al. | Mar 2007 | A1 |
20070173784 | Johansson et al. | Jul 2007 | A1 |
20070197956 | Le et al. | Aug 2007 | A1 |
20070198028 | Miloslayski et al. | Aug 2007 | A1 |
20070198049 | Barbut | Aug 2007 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080140010 | Kennedy et al. | Jun 2008 | A1 |
20080177245 | Mesallum | Jul 2008 | A1 |
20080200946 | Braun et al. | Aug 2008 | A1 |
20080255475 | Kondrosky et al. | Oct 2008 | A1 |
20090018455 | Chang | Jan 2009 | A1 |
20090024072 | Criado et al. | Jan 2009 | A1 |
20090030400 | Bose et al. | Jan 2009 | A1 |
20090198172 | Garrison et al. | Aug 2009 | A1 |
20090254166 | Chou et al. | Oct 2009 | A1 |
20090299393 | Martin et al. | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100030186 | Stivland | Feb 2010 | A1 |
20100042118 | Garrison et al. | Feb 2010 | A1 |
20100049147 | Tanikawa et al. | Feb 2010 | A1 |
20100063479 | Merdan et al. | Mar 2010 | A1 |
20100063480 | Shireman | Mar 2010 | A1 |
20100094330 | Barbut | Apr 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100145308 | Layman et al. | Jun 2010 | A1 |
20100185216 | Garrison et al. | Jul 2010 | A1 |
20100204672 | Lockhart et al. | Aug 2010 | A1 |
20100204684 | Garrison et al. | Aug 2010 | A1 |
20100217276 | Garrison et al. | Aug 2010 | A1 |
20100228269 | Garrison et al. | Sep 2010 | A1 |
20100256600 | Ferrera | Oct 2010 | A1 |
20100280431 | Criado et al. | Nov 2010 | A1 |
20100318097 | Ferrera et al. | Dec 2010 | A1 |
20110004147 | Renati et al. | Jan 2011 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110034986 | Chou et al. | Feb 2011 | A1 |
20110087147 | Garrison et al. | Apr 2011 | A1 |
20110112567 | Lenker et al. | May 2011 | A1 |
20110125131 | Chang | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110152760 | Parker | Jun 2011 | A1 |
20110166496 | Criado et al. | Jul 2011 | A1 |
20110166497 | Criado et al. | Jul 2011 | A1 |
20110238041 | Lim et al. | Sep 2011 | A1 |
20120095485 | Cully et al. | Apr 2012 | A1 |
20120109044 | Santamore et al. | May 2012 | A1 |
20120179097 | Cully et al. | Jul 2012 | A1 |
20120238956 | Yamada et al. | Sep 2012 | A1 |
20120310212 | Fischell et al. | Dec 2012 | A1 |
20130035628 | Garrison et al. | Feb 2013 | A1 |
20130172852 | Chang | Jul 2013 | A1 |
20130184735 | Fischell et al. | Jul 2013 | A1 |
20130197621 | Ryan et al. | Aug 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20140031682 | Renati et al. | Jan 2014 | A1 |
20140031925 | Garrison et al. | Jan 2014 | A1 |
20140046297 | Shimada et al. | Feb 2014 | A1 |
20140046346 | Hentges et al. | Feb 2014 | A1 |
20140058414 | Garrison et al. | Feb 2014 | A1 |
20140135661 | Garrison et al. | May 2014 | A1 |
20140155783 | Starksen et al. | Jun 2014 | A1 |
20140236120 | Tsai et al. | Aug 2014 | A1 |
20140257018 | Farnan | Sep 2014 | A1 |
20140257186 | Kerr | Sep 2014 | A1 |
20140296769 | Hyde et al. | Oct 2014 | A1 |
20140296868 | Garrison et al. | Oct 2014 | A1 |
20140371653 | Criado et al. | Dec 2014 | A1 |
20150025616 | Chang | Jan 2015 | A1 |
20150080942 | Garrison et al. | Mar 2015 | A1 |
20150141760 | Chou et al. | May 2015 | A1 |
20150150562 | Chang | Jun 2015 | A1 |
20150173782 | Garrison et al. | Jun 2015 | A1 |
20150174368 | Garrison et al. | Jun 2015 | A1 |
20150327843 | Garrison | Nov 2015 | A1 |
20160008025 | Gupta et al. | Jan 2016 | A1 |
20160128688 | Garrison et al. | May 2016 | A1 |
20160158044 | Chou et al. | Jun 2016 | A1 |
20160158502 | Kume et al. | Jun 2016 | A1 |
20160166804 | Garrison et al. | Jun 2016 | A1 |
20160242764 | Garrison et al. | Aug 2016 | A1 |
20160271315 | Chang | Sep 2016 | A1 |
20160271316 | Criado et al. | Sep 2016 | A1 |
20160279379 | Chang | Sep 2016 | A1 |
20160296690 | Kume et al. | Oct 2016 | A1 |
20170043141 | Kume et al. | Feb 2017 | A1 |
20170136212 | Garrison et al. | May 2017 | A1 |
20170209260 | Garrison et al. | Jul 2017 | A1 |
20170296798 | Kume et al. | Oct 2017 | A1 |
20170312491 | Ryan et al. | Nov 2017 | A1 |
20170354523 | Chou et al. | Dec 2017 | A1 |
20170354803 | Kume et al. | Dec 2017 | A1 |
20170361072 | Chou et al. | Dec 2017 | A1 |
20170368296 | Chang | Dec 2017 | A1 |
20180008294 | Garrison et al. | Jan 2018 | A1 |
20180154063 | Criado et al. | Jun 2018 | A1 |
20180185614 | Garrison et al. | Jul 2018 | A1 |
20180289884 | Criado et al. | Oct 2018 | A1 |
20190105439 | Criado et al. | Apr 2019 | A1 |
20190150916 | Hentges et al. | May 2019 | A1 |
20190231962 | Criado et al. | Aug 2019 | A1 |
20190254680 | Chang | Aug 2019 | A1 |
20190262530 | Criado et al. | Aug 2019 | A1 |
20190269538 | Chou et al. | Sep 2019 | A1 |
20190350568 | Garrison | Nov 2019 | A1 |
20190388654 | Chou et al. | Dec 2019 | A1 |
20200009406 | Garrison et al. | Jan 2020 | A1 |
20200015826 | Chang | Jan 2020 | A1 |
20200016321 | Criado et al. | Jan 2020 | A1 |
20200038576 | Garrison et al. | Feb 2020 | A1 |
20200054871 | Ryan et al. | Feb 2020 | A1 |
20200108221 | Chang | Apr 2020 | A1 |
20200113587 | Garrison et al. | Apr 2020 | A1 |
20200170637 | Garrison et al. | Jun 2020 | A1 |
20200171277 | Garrison et al. | Jun 2020 | A1 |
Number | Date | Country |
---|---|---|
101267781 | Sep 2008 | CN |
102223909 | Oct 2011 | CN |
102006039236 | Feb 2008 | DE |
0427429 | May 1991 | EP |
1440663 | Jul 2004 | EP |
H02-71764 | Mar 1990 | JP |
H04-263870 | Sep 1992 | JP |
H7-148264 | Jun 1995 | JP |
2009-535084 | Oct 2009 | JP |
2013-048881 | Mar 2013 | JP |
2014-521462 | Aug 2014 | JP |
WO-9505209 | Feb 1995 | WO |
WO-9838930 | Sep 1998 | WO |
WO-9945835 | Sep 1999 | WO |
WO-0032266 | Jun 2000 | WO |
WO-0076390 | Dec 2000 | WO |
WO-0115767 | Mar 2001 | WO |
WO-0158365 | Aug 2001 | WO |
WO-0232495 | Apr 2002 | WO |
WO-03018085 | Mar 2003 | WO |
WO-03090831 | Nov 2003 | WO |
WO-2004006803 | Jan 2004 | WO |
WO-2005051206 | Jun 2005 | WO |
WO-2007046348 | Apr 2007 | WO |
WO-2007125488 | Nov 2007 | WO |
WO-2008123521 | Oct 2008 | WO |
WO-2008144587 | Nov 2008 | WO |
WO-2009012473 | Jan 2009 | WO |
WO-2009099764 | Aug 2009 | WO |
WO-2009100210 | Aug 2009 | WO |
WO-2010075445 | Jul 2010 | WO |
WO-2010075565 | Jul 2010 | WO |
WO-2012047803 | Apr 2012 | WO |
WO-2013022796 | Feb 2013 | WO |
WO-2015175537 | Nov 2015 | WO |
WO-2016018781 | Feb 2016 | WO |
WO-2016036660 | Mar 2016 | WO |
WO-2016137875 | Sep 2016 | WO |
Entry |
---|
Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154. |
Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European CAST I Study” J. Endovasc. Surg. 6:155 159. |
Bergeron et al. (2008) MEET Presentation, Cannes, French Riviera “Why I do not use routine femoral access for CAS”. 12 pages. |
Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79. |
Bourekas, E. C., A. P. Slivka, et al. (2004). “Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.” Neurosurgery 54(1): 39-44; discussion 44-6. |
Cohen et al., “A reappraisal of the common carotid artery as an access site in interventional procedures for acute stroke therapies”, Case Reports, Journal of Clinical Neuroscience 19 (2012) pp. 323-326. |
Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114. |
Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633. |
Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202. |
Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136. |
Feldtman, R. W., C. J. Buckley, et al. (2006). “How I do it: cervical access for carotid artery stenting.” Am J Surg 192(6): 779-81. |
Fiorella, D., M. Kelly, et al. (2008). “Endovascular Treatment of Cerebral Aneurysms.” Endovascular Today Jun. 2008. pp. 53-64. |
Frazee, J. G. and X. Luo (1999). “Retrograde transvenous perfusion.” Crit Care Clin 15(4): 777-88, vii. |
Frazee, J. G., X. Luo, et al. (1998). “Retrograde transvenous neuroperfusion: a back door treatment for stroke.” Stroke 29(9): 1912-6. |
Goldstein “Acute Ischemic Stroke Treatment in 2007” Circ 116:1504-1514 (2007). |
Gray et al. (2007) “The CAPTURE registry: Results of carotid stenting with embolic protection in the post approval setting” Cath. Cardovasc. Interven. 69:341-348. |
Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331. |
Hoffer et al. “Percutaneous Arterial Closure Devices” J. Vasc. Interv. Radiol. 14:865-885 (2003). |
Howell, M., K. Doughtery, et al. (2002). “Percutaneous repair of abdominal aortic aneurysms using the AneuRx stent graft and the percutaneous vascular surgery device.” Catheter Cardiovasc Intery 55(3): 281-7. |
Koebbe, C. J., E. Veznedaroglu, et al. (2006). “Endovascular management of intracranial aneurysms: current experience and future advances.” Neurosurgery 59(5 Suppl 3): S93-102; discussion S3-13. |
Luebke, T et al. (2007) “Meta-analysis of randomized trials comparing carotid endarterectomy and endovascular treatment” Eur. J. Vasc. Endovasc. Surg. 34:470-479. |
MacDonald, S. (2006) “Is there any evidence that cerebral protection is beneficial?” J. Cardiovasc. Surg. 47:127-36. |
Mas et al. (2006) “Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis” NEJM 355:1660-71. |
MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. 37 pages. |
Nesbit, G. M., G. Luh, et al. (2004). “New and future endovascular treatment strategies for acute ischemic stroke.” J Vasc Intery Radiol 15(1 Pt 2): S103-10. |
Nii, K., K. Kazekawa, et al. (2006). “Direct carotid puncture for the endovascular treatment of anterior circulation aneurysms.” AJNR Am J Neuroradiol 27(7): 1502-4. |
Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80. |
Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136. |
Parodi, J. C., L. M. Ferreira, et al. (2005). “Cerebral protection during carotid stenting using flow reversal.” J Vasc Surg 41(3): 416-22. |
Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41. |
Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3. |
Reimers et al. (2005). “Proximal endovascular flow blockage for cerebral protection during carotid artery stenting: Results froma prospective multicenter registry” J. Endovasc. Ther. 12:156-165. |
Ribo, M., C. Molina, et al. (2008). “Buying Time for Recanalization in Acute Stroke: Arterial Blood Infusion Beyond the Occluding Clot as a Neuroprotective Strategy.” J Neuroimaging. 4 pages. |
Ross, I. B. and G. D. Luzardo (2006). “Direct access to the carotid circulation by cut down for endovascular neuro-interventions.” Surg Neurol 65(2): 207-11; discussion 211. |
Stejskal et al., “Experience of 500 Cases of Neurophysiological Monitoring in Carotid Endarterectomy”, Acta Neurochir, 2007, 149:681-689. |
Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection” AJNR 11:869-874, Sep./Oct. 1990 0195-6108/90/1106-0869 @ American Society of Neurology. |
U.S. Appl. No. 12/645,179, filed Dec. 22, 2009, Publ. No. US 2010-0217276. |
U.S. Appl. No. 13/961,746, filed Aug. 7, 2013, Publ. No. US 2014-0046346. |
U.S. Appl. No. 14/078,149, filed Nov. 12, 2013, Publ. No. US 2014-0135661. |
U.S. Appl. No. 14/710,400, filed May 12, 2015, Publ. No. US 2015-0327843. |
U.S. Appl. No. 14/935,252, filed Nov. 6, 2015, Publ. No. US 2016-0128688. |
U.S. Appl. No. 15/093,406, filed Apr. 7, 2016, Publ. No. US 2016-0296690. |
U.S. Appl. No. 15/168,786, filed May 31, 2016, Publ. No. US 2016-0271315. |
U.S. Appl. No. 15/489,055, filed Apr. 17, 2017, Publ. No. US 2017-0312491. |
U.S. Appl. No. 15/613,891, filed Jun. 5, 2017, Publ. No. US 2017-0361072. |
U.S. Appl. No. 15/613,921, filed Jun. 5, 2017, Publ. No. US 2017-0368296. |
U.S. Appl. No. 15/628,190, filed Jun. 20, 2017, Publ. No. US 2018-0008294. |
U.S. Appl. No. 15/728,747, filed Oct. 10, 2017, Publ. No. US 2018-0154063. |
U.S. Appl. No. 15/728,915, filed Oct. 10, 2017, Publ. No. US 2018-0185614. |
U.S. Appl. No. 16/008,703, filed Jun. 14, 2018, Publ. No. US 2018-0289884. |
Int'l App. No. PCT/US18/18943, filed Feb. 21, 2018, Publ. No. WO 2018/156574. |
U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, Publ. No. US 2014-0296769. |
U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, Publ. No. US 2016-0242764. |
U.S. Appl. No. 15/141,060, filed Apr. 28, 2016, Publ. No. US 2016-0317288. |
U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, Publ. No. US 2017-0209260. |
U.S. Appl. No. 15/641,966, filed Jul. 5, 2017, Publ. No. US 2017-0296798. |
U.S. Appl. No. 15/901,502, filed Feb. 21, 2018, Publ. No. US 2018-0235789. |
U.S. Appl. No. 16/148,849, filed Oct. 1, 2018, Publ. No. US 2019-0269538. |
U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, Publ. No. US 2019-0125512. |
U.S. Appl. No. 16/177,716, filed Nov. 1, 2018, Publ. No. US 2019-0150916. |
U.S. Appl. No. 16/250,825, filed Jan. 17, 2019, Publ. No. US 2019-0350568. |
U.S. Appl. No. 16/256,229, filed Jan. 24, 2019, Publ. No. US 2019-0254680. |
U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, Publ. No. US 2019-0388654. |
U.S. Appl. No. 16/297,348, filed Mar. 8, 2019, Publ. No. US 2020-0038576. |
U.S. Appl. No. 16/299,524, filed Mar. 12, 2019, Publ. No. US 2019-0366070. |
U.S. Appl. No. 16/353,492, filed Mar. 14, 2019, Publ. No. US 2020-0009406. |
U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, Publ. No. US 2019-0231962. |
U.S. Appl. No. 16/411,543, filed May 14, 2019, Publ. No. US 2020-0108221. |
U.S. Appl. No. 16/513,030, filed Jul. 16, 2019, Publ. No. US 2020-0170637. |
U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, Publ. No. US 2020-0054871. |
U.S. Appl. No. 16/544,083, filed Aug. 19, 2019, Publ. No. US 2020-0171277. |
U.S. Appl. No. 16/547,042, filed Aug. 21, 2019, Publ. No. US 2020-0113587. |
U.S. Appl. No. 16/581,034, filed Sep. 24, 2019, Publ. No. US 2020-0015826. |
Number | Date | Country | |
---|---|---|---|
20190175885 A1 | Jun 2019 | US |
Number | Date | Country | |
---|---|---|---|
62075169 | Nov 2014 | US | |
62046112 | Sep 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15606381 | May 2017 | US |
Child | 16056208 | US | |
Parent | 15210770 | Jul 2016 | US |
Child | 15606381 | US | |
Parent | 15005770 | Jan 2016 | US |
Child | 15210770 | US | |
Parent | 14575199 | Dec 2014 | US |
Child | 15005770 | US | |
Parent | 14537316 | Nov 2014 | US |
Child | 14575199 | US |